{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:41:54Z","timestamp":1781631714853,"version":"3.54.5"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010167","name":"Shanghai Shen Kang Hospital Development Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Integrative Medicine"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.joim.2020.12.006","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T02:22:37Z","timestamp":1609208557000},"page":"120-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pingchan granule for depressive symptoms in parkinson\u2019s disease: A randomized, double-blind, placebo-controlled trial"],"prefix":"10.1016","volume":"19","author":[{"given":"Si-chun","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can-xing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.joim.2020.12.006_b0005","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.joim.2020.12.006_b0010","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrn.2017.62","article-title":"Non-motor features of Parkinson disease","volume":"18","author":"Schapira","year":"2017","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"10.1016\/j.joim.2020.12.006_b0015","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1212\/01.wnl.0000268695.63392.10","article-title":"The impact of depressive symptoms in early Parkinson disease","volume":"69","author":"Ravina","year":"2007","journal-title":"Neurology"},{"issue":"9996","key":"10.1016\/j.joim.2020.12.006_b0020","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.joim.2020.12.006_b0025","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/mds.20723","article-title":"Provisional diagnostic criteria for depression in Parkinson's disease: Report of an NINDS\/NIMH Work Group","volume":"21","author":"Marsh","year":"2006","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.joim.2020.12.006_b0030","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/archneur.1992.00530270125028","article-title":"An estimate of the incidence of depression in idiopathic Parkinson's disease","volume":"49","author":"Dooneief","year":"1992","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.joim.2020.12.006_b0035","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/archneur.1996.00550020087019","article-title":"The occurrence of depression in Parkinson\u2019s disease. A community-based study","volume":"53","author":"Tandberg","year":"1996","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.joim.2020.12.006_b0040","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/mds.21803","article-title":"A systematic review of prevalence studies of depression in Parkinson's disease: The Prevalence of Depression in PD","volume":"23","author":"Reijnders","year":"2008","journal-title":"Mov Disord"},{"issue":"10","key":"10.1016\/j.joim.2020.12.006_b0045","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.4103\/1673-5374.193242","article-title":"Anti-apoptotic effect of Shudipingchan granule in the substantia nigra of rat models of Parkinson\u2032s disease","volume":"11","author":"Ye","year":"2016","journal-title":"Neural Regen Res"},{"issue":"7","key":"10.1016\/j.joim.2020.12.006_b0050","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.4103\/1673-5374.235075","article-title":"Zishenpingchan granules for the treatment of Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled clinical trial","volume":"13","author":"Ye","year":"2018","journal-title":"Neural Regen Res"},{"issue":"12","key":"10.1016\/j.joim.2020.12.006_b0055","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease: MDS-PD Clinical Diagnostic Criteria","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"issue":"10 Suppl 3","key":"10.1016\/j.joim.2020.12.006_b0060","first-page":"S11","article-title":"Parkinsonism: onset, progression and mortality. 1967","volume":"57","author":"Hoehn","year":"2001","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.joim.2020.12.006_b0065","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/mds.21333","article-title":"Depression rating scales in Parkinson's disease: Critique and recommendations","volume":"22","author":"Schrag","year":"2007","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.joim.2020.12.006_b0070","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mds.870090112","article-title":"Unified Parkinson\u2019s Disease Rating Scale characteristics and structure","volume":"9","author":"Martinez-Martin","year":"1994","journal-title":"The Cooperative Multicentric Group Mov Disord"},{"issue":"6","key":"10.1016\/j.joim.2020.12.006_b0075","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/jnnp.73.6.629","article-title":"The Parkinson\u2019s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson\u2019s disease","volume":"73","author":"Chaudhuri","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.joim.2020.12.006_b0080","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mds.23184","article-title":"Anxiety rating scales in Parkinson's disease: A validation study of the Hamilton anxiety rating scale, the Beck anxiety inventory, and the hospital anxiety and depression scale: Validation of Anxiety Rating Scales in PD","volume":"26","author":"Leentjens","year":"2011","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.joim.2020.12.006_b0085","doi-asserted-by":"crossref","first-page":"548","DOI":"10.33314\/jnhrc.v17i4.1042","article-title":"The Declaration of Helsinki on medical research involving human subjects: a review of seventh revision","volume":"17","author":"Shrestha","year":"2020","journal-title":"J Nepal Health Res Counc"},{"issue":"1","key":"10.1016\/j.joim.2020.12.006_b0090","doi-asserted-by":"crossref","DOI":"10.2349\/biij.4.1.e5","article-title":"The importance of Good Clinical Practice guidelines and its role in clinical trials","volume":"4","author":"Vijayananthan","year":"2008","journal-title":"Biomed Imaging Interv J"},{"key":"10.1016\/j.joim.2020.12.006_b0095","series-title":"Sample size calculations in clinical research","first-page":"50","author":"Chow","year":"2008"},{"issue":"15","key":"10.1016\/j.joim.2020.12.006_b0100","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson's disease: Systematic Review of LED Reporting in PD","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.joim.2020.12.006_b0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1353-8020(99)00051-6","article-title":"Parkinson's disease subtypes: clinical classification and ventricular cerebrospinal fluid analysis","volume":"6","author":"Schiess","year":"2000","journal-title":"Parkins Related Disord"},{"issue":"1","key":"10.1016\/j.joim.2020.12.006_b0110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1192\/bjp.141.1.45","article-title":"A comparison of depression rating scales","volume":"141","author":"Kearns","year":"1982","journal-title":"Br J Psychiatry"},{"issue":"2","key":"10.1016\/j.joim.2020.12.006_b0115","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00001648-199203000-00013","article-title":"Identifiability and exchangeability for direct and indirect effects","volume":"3","author":"Robins","year":"1992","journal-title":"Epidemiology"},{"issue":"3","key":"10.1016\/j.joim.2020.12.006_b0120","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3758\/BRM.40.3.879","article-title":"Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models","volume":"40","author":"Preacher","year":"2008","journal-title":"Behav Res Methods"},{"issue":"4","key":"10.1016\/j.joim.2020.12.006_b0125","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1037\/met0000021","article-title":"Comment on Pearl: practical implications of theoretical results for causal mediation analysis","volume":"19","author":"Imai","year":"2014","journal-title":"Psychol Methods"},{"key":"10.1016\/j.joim.2020.12.006_b0130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jad.2020.02.046","article-title":"Personalized prediction of depression in patients with newly diagnosed Parkinson\u2019s disease: A prospective cohort study","volume":"268","author":"Gu","year":"2020","journal-title":"J Affect Disord"},{"issue":"7","key":"10.1016\/j.joim.2020.12.006_b0135","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.parkreldis.2014.03.020","article-title":"Systematic review of factors associated with depression and anxiety disorders among older adults with Parkinson's disease","volume":"20","author":"Sagna","year":"2014","journal-title":"Parkins Related Disord"},{"issue":"4","key":"10.1016\/j.joim.2020.12.006_b0140","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/ene.13551","article-title":"Vascular risk factors and depression in Parkinson's disease","volume":"25","author":"Ou","year":"2018","journal-title":"Eur J Neurol"},{"issue":"12","key":"10.1016\/j.joim.2020.12.006_b0145","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1212\/WNL.0b013e3182a4a503","article-title":"Modeling depression in Parkinson disease: Disease-specific and nonspecific risk factors","volume":"81","author":"Leentjens","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.joim.2020.12.006_b0150","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.physbeh.2017.01.046","article-title":"Chronic mild stress augments MPTP induced neurotoxicity in a murine model of Parkinson's disease","volume":"173","author":"Janakiraman","year":"2017","journal-title":"Physiol Behav"},{"issue":"12","key":"10.1016\/j.joim.2020.12.006_b0155","doi-asserted-by":"crossref","first-page":"E4471","DOI":"10.3390\/ijms21124471","article-title":"MAP\/ERK signaling in developing cognitive and emotional function and its effect on pathological and neurodegenerative processes","volume":"21","author":"Albert-Gasco","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"16","key":"10.1016\/j.joim.2020.12.006_b0160","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e3182516244","article-title":"A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease","volume":"78","author":"Richard","year":"2012","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.joim.2020.12.006_b0165","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","article-title":"A controlled trial of antidepressants in patients with Parkinson disease and depression","volume":"72","author":"Menza","year":"2009","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.joim.2020.12.006_b0170","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/mds.21966","article-title":"Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double-blind, randomized, placebo-controlled study: Depression in Parkinson's Disease","volume":"23","author":"Devos","year":"2008","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.joim.2020.12.006_b0175","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1468-1331.2003.00612.x","article-title":"Pramipexole and pergolide in the treatment of depression in Parkinson\u2019s disease: a national multicentre prospective randomized study","volume":"10","author":"Rektorova","year":"2003","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1016\/j.joim.2020.12.006_b0180","first-page":"707","article-title":"Beneficial effect of pramipexole for motor function and depression in Parkinson\u2019s disease","volume":"4","author":"Kano","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"10.1016\/j.joim.2020.12.006_b0185","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H","article-title":"Comparison of pramipexole, fluoxetine, and placebo in patients with major depression","volume":"11","author":"Corrigan","year":"2000","journal-title":"Depress Anxiety"},{"issue":"3","key":"10.1016\/j.joim.2020.12.006_b0190","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/npp.2008.114","article-title":"Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain","volume":"34","author":"Chernoloz","year":"2009","journal-title":"Neuropsychopharmacol"},{"issue":"6","key":"10.1016\/j.joim.2020.12.006_b0195","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","article-title":"Pramipexole for the treatment of depressive symptoms in patients with Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial","volume":"9","author":"Barone","year":"2010","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.joim.2020.12.006_b0200","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.psych.59.113006.095941","article-title":"A comprehensive review of the placebo effect: recent advances and current thought","volume":"59","author":"Price","year":"2008","journal-title":"Annu Rev Psychol"},{"issue":"5532","key":"10.1016\/j.joim.2020.12.006_b0205","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1126\/science.1060937","article-title":"Expectation and dopamine release: mechanism of the placebo effect in Parkinson\u2019s disease","volume":"293","author":"de la Fuente-Fernandez","year":"2001","journal-title":"Science"},{"issue":"45","key":"10.1016\/j.joim.2020.12.006_b0210","doi-asserted-by":"crossref","first-page":"10390","DOI":"10.1523\/JNEUROSCI.3458-05.2005","article-title":"Neurobiological mechanisms of the placebo effect","volume":"25","author":"Benedetti","year":"2005","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.joim.2020.12.006_b0215","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0957154X17741783","article-title":"Understanding the DSM-5: stasis and change","volume":"29","author":"Cooper","year":"2018","journal-title":"Hist Psychiatry"}],"container-title":["Journal of Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095496420301497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095496420301497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:50:51Z","timestamp":1761864651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095496420301497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2095496420301497"],"URL":"https:\/\/doi.org\/10.1016\/j.joim.2020.12.006","relation":{},"ISSN":["2095-4964"],"issn-type":[{"value":"2095-4964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pingchan granule for depressive symptoms in parkinson\u2019s disease: A randomized, double-blind, placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Integrative Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joim.2020.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Shanghai Changhai Hospital. Published by ELSEVIER B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}